Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

Read the news release
Visit BioReference Health

Long-Acting Biologics & Peptides

Long-Acting Technologies for Everyday Life

OPKO’s long-acting platforms for biologics and peptide are designed to keep medicines active in the body for longer, with the goal of reducing dosing frequency, smoothing drug exposure and improving the overall treatment experience for people living with chronic disease.

Versatile Platforms Across Multiple Therapeutic Areas

We’re combining proprietary technologies that significantly extend a drug’s half‑life utilizing advanced peptide and protein engineering.

See Our Pipeline

Validated Technology with Commercial Medicines

NGENLA® (somatrogon-ghla), an approved once‑weekly growth hormone developed with Pfizer, is a once per week injection for children with growth hormone deficiency.

Learn About NGENLA

Leveraging Partnerships to Advance Programs

OPKO is advancing additional long‑acting peptide candidates, including next‑generation PTH and oxyntomodulin analogs being developed with Entera Bio.

Visit Entera Bio